Biotech6 months ago
Biotest Forecasts US Sales of Yimmugo of 936 Million Over the Next 7 Years
Biotest, a Grifols group company, expects $1 billion in US sales of its immunoglobulin drug Yimmugo over the next seven years, following FDA approval. Grifols shares...